Steering diagnostic innovation to address the unmet needs in managing lung infections in people with cystic fibrosis

On June 5th 2024, the Cystic Fibrosis (CF) Antimicrobial Resistance (AMR) Syndicate launched their diagnostic target product profiles (TPPs) detailing key characteristics of new tests needed to detect and manage lung infections and exacerbations in CF. The CF AMR Syndicate together with the Newcastle NIHR HealthTech Research Centre (HRC), have undertaken extensive engagement with a broad range of experts across…